Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

BioSpace

Analysts will be watching as a generic version of semaglutide--marketed by Novo Nordisk as Wegovy for weight loss--launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

BioSpace

Analysts will be watching as a generic version of semaglutide–marketed by Novo Nordisk as Wegovy for weight loss–launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

Related Stories

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Pfizer deals extend patent life for a top-selling rare disease drug

You May Have Missed

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

AZ, Amgen will pilot FDA’s real-time clinical trial plan

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’